BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 19741299)

  • 1. Cdc42 is an antihypertrophic molecular switch in the mouse heart.
    Maillet M; Lynch JM; Sanna B; York AJ; Zheng Y; Molkentin JD
    J Clin Invest; 2009 Oct; 119(10):3079-88. PubMed ID: 19741299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cooperative Binding of ETS2 and NFAT Links Erk1/2 and Calcineurin Signaling in the Pathogenesis of Cardiac Hypertrophy.
    Luo Y; Jiang N; May HI; Luo X; Ferdous A; Schiattarella GG; Chen G; Li Q; Li C; Rothermel BA; Jiang D; Lavandero S; Gillette TG; Hill JA
    Circulation; 2021 Jul; 144(1):34-51. PubMed ID: 33821668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy.
    Wilkins BJ; Dai YS; Bueno OF; Parsons SA; Xu J; Plank DM; Jones F; Kimball TR; Molkentin JD
    Circ Res; 2004 Jan; 94(1):110-8. PubMed ID: 14656927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac-specific deletion of mkk4 reveals its role in pathological hypertrophic remodeling but not in physiological cardiac growth.
    Liu W; Zi M; Jin J; Prehar S; Oceandy D; Kimura TE; Lei M; Neyses L; Weston AH; Cartwright EJ; Wang X
    Circ Res; 2009 Apr; 104(7):905-14. PubMed ID: 19265040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TAK1 Regulates Myocardial Response to Pathological Stress via NFAT, NFκB, and Bnip3 Pathways.
    Li L; Chen Y; Li J; Yin H; Guo X; Doan J; Molkentin JD; Liu Q
    Sci Rep; 2015 Nov; 5():16626. PubMed ID: 26564789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. c-Jun N-terminal kinases (JNK) antagonize cardiac growth through cross-talk with calcineurin-NFAT signaling.
    Liang Q; Bueno OF; Wilkins BJ; Kuan CY; Xia Y; Molkentin JD
    EMBO J; 2003 Oct; 22(19):5079-89. PubMed ID: 14517246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs.
    Molkentin JD
    Cardiovasc Res; 2004 Aug; 63(3):467-75. PubMed ID: 15276472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TRPC channels are necessary mediators of pathologic cardiac hypertrophy.
    Wu X; Eder P; Chang B; Molkentin JD
    Proc Natl Acad Sci U S A; 2010 Apr; 107(15):7000-5. PubMed ID: 20351294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac anti-remodelling effect of aerobic training is associated with a reduction in the calcineurin/NFAT signalling pathway in heart failure mice.
    Oliveira RS; Ferreira JC; Gomes ER; Paixão NA; Rolim NP; Medeiros A; Guatimosim S; Brum PC
    J Physiol; 2009 Aug; 587(Pt 15):3899-910. PubMed ID: 19505981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling.
    Braz JC; Bueno OF; Liang Q; Wilkins BJ; Dai YS; Parsons S; Braunwart J; Glascock BJ; Klevitsky R; Kimball TF; Hewett TE; Molkentin JD
    J Clin Invest; 2003 May; 111(10):1475-86. PubMed ID: 12750397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction between NFκB and NFAT coordinates cardiac hypertrophy and pathological remodeling.
    Liu Q; Chen Y; Auger-Messier M; Molkentin JD
    Circ Res; 2012 Apr; 110(8):1077-86. PubMed ID: 22403241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced expression of DYRK1A in cardiomyocytes inhibits acute NFAT activation but does not prevent hypertrophy in vivo.
    Grebe C; Klingebiel TM; Grau SP; Toischer K; Didié M; Jacobshagen C; Dullin C; Hasenfuss G; Seidler T
    Cardiovasc Res; 2011 Jun; 90(3):521-8. PubMed ID: 21273244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct and indirect interactions between calcineurin-NFAT and MEK1-extracellular signal-regulated kinase 1/2 signaling pathways regulate cardiac gene expression and cellular growth.
    Sanna B; Bueno OF; Dai YS; Wilkins BJ; Molkentin JD
    Mol Cell Biol; 2005 Feb; 25(3):865-78. PubMed ID: 15657416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TRPC6 fulfills a calcineurin signaling circuit during pathologic cardiac remodeling.
    Kuwahara K; Wang Y; McAnally J; Richardson JA; Bassel-Duby R; Hill JA; Olson EN
    J Clin Invest; 2006 Dec; 116(12):3114-26. PubMed ID: 17099778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ASK1 regulates cardiomyocyte death but not hypertrophy in transgenic mice.
    Liu Q; Sargent MA; York AJ; Molkentin JD
    Circ Res; 2009 Nov; 105(11):1110-7. PubMed ID: 19815822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Muscle-specific RING finger 1 negatively regulates pathological cardiac hypertrophy through downregulation of calcineurin A.
    Maejima Y; Usui S; Zhai P; Takamura M; Kaneko S; Zablocki D; Yokota M; Isobe M; Sadoshima J
    Circ Heart Fail; 2014 May; 7(3):479-90. PubMed ID: 24526353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polydatin attenuates cardiac hypertrophy through modulation of cardiac Ca2+ handling and calcineurin-NFAT signaling pathway.
    Ding W; Dong M; Deng J; Yan D; Liu Y; Xu T; Liu J
    Am J Physiol Heart Circ Physiol; 2014 Sep; 307(5):H792-802. PubMed ID: 25015961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen attenuates left ventricular and cardiomyocyte hypertrophy by an estrogen receptor-dependent pathway that increases calcineurin degradation.
    Donaldson C; Eder S; Baker C; Aronovitz MJ; Weiss AD; Hall-Porter M; Wang F; Ackerman A; Karas RH; Molkentin JD; Patten RD
    Circ Res; 2009 Jan; 104(2):265-75, 11p following 275. PubMed ID: 19074476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LIM and cysteine-rich domains 1 regulates cardiac hypertrophy by targeting calcineurin/nuclear factor of activated T cells signaling.
    Bian ZY; Huang H; Jiang H; Shen DF; Yan L; Zhu LH; Wang L; Cao F; Liu C; Tang QZ; Li H
    Hypertension; 2010 Feb; 55(2):257-63. PubMed ID: 20026769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carabin protects against cardiac hypertrophy by blocking calcineurin, Ras, and Ca2+/calmodulin-dependent protein kinase II signaling.
    Bisserier M; Berthouze-Duquesnes M; Breckler M; Tortosa F; Fazal L; de Régibus A; Laurent AC; Varin A; Lucas A; Branchereau M; Marck P; Schickel JN; Deloménie C; Cazorla O; Soulas-Sprauel P; Crozatier B; Morel E; Heymes C; Lezoualc'h F
    Circulation; 2015 Jan; 131(4):390-400; discussion 400. PubMed ID: 25369805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.